

 Waikato District Health Board		Type: Drug Guideline	Document reference: 2936	Manual Classification: Waikato DHB Drug Guidelines
Title: Magnesium for neonates			Effective date: 28 February 2022	
Facilitator <small>sign/date</small> <i>Kerrie Knox</i> Pharmacist	Authorised <small>sign/date</small> <i>Jutta van den Boom</i> Clinical Director NICU	Authorised <small>sign/date</small> <i>John Barnard</i> Chair Medicines & Therapeutics	Version: 1	Page: 1 of 2
			Document expiry date: 28 February 2025	

© Waikato DHB, May 2022

BRIEF ADMINISTRATION GUIDE

For detailed information refer to [The Australasian Neonatal Medicines Formulary magnesium guideline](#)



Critical Note: there are minor variations between the ANMF and Waikato DHB best practice within this drug guideline – see shaded text

Indications: Hypomagnesaemia (magnesium <0.7 mmol/L)

Note: magnesium can be used for many other conditions – refer to other guidelines

Route: Intravenous, intramuscular

- Injection supplied as magnesium sulfate (heptahydrate) 50% (500 mg/ml), 2 mmol/mL elemental magnesium, 5 ml glass ampoule
 - pH of magnesium is 5.5 – 7

Dose: 0.1 – 0.2 mmol/kg/dose elemental magnesium
Severe cases may require up to 0.4 mmol/kg/dose
Repeat dose as necessary every 6 to 12 hours
Reduce dose in renal impairment

Preparation and administration

Compatible fluids: glucose 5%, sodium chloride 0.9%, glucose 5% in sodium chloride, parenteral nutrition

Intermittent Intravenous Infusion

- Dilute 2 mL (4 mmol) of magnesium with 6 mL of compatible fluid to make 8 mL of a 0.5 mmol/mL solution. Maximum concentration if fluid restricted is 0.8 mmol/mL (see under IM for preparation).
- Administer prescribed dose over 30 to 60 minutes
Note: while magnesium can be given more rapidly in emergencies e.g. over 10-20 minutes, rapid infusions may cause hypotension and circulatory collapse and retention is also reduced

Intramuscular Injection

- Dilute 2 mL (4 mmol) of magnesium with 3 mL of compatible fluid to make 5 mL of a 0.8 mmol/mL solution
- Administer prescribed dose by intramuscular injection into vastus lateralis muscle of the thigh

Monitoring

- Continuous cardiorespiratory monitoring
- Blood pressure, respiratory rate, heart rate, oxygen saturation, and fluid balance periodically during treatment
- Check magnesium levels and for signs of toxicity (e.g. nausea, vomiting, flushing, hypotension, muscle paralysis, CNS depression) at periodic intervals. Usual range 0.75 – 1 mmol/L.
- Monitor serum calcium, sodium, potassium and renal function regularly during treatment
- **Note:** if receiving concomitant aminoglycosides, monitor for neuromuscular weakness (e.g. respiratory compromise)

 Waikato District Health Board	Document reference: 2936	Effective date: 28 Feb 2022	Expiry date: 28 Feb 2025	Page: 2 of 2
	Title: Magnesium for neonates	Type: Drug Guideline	Version: 1	Authorising initials:

Storage and Stability

- Diluted solutions are stable at room temperature (below 25°C) for up to 24 hours

Competency for administration

This procedure is carried out by, or under, the direct supervision of a registered nurse/registered midwife who holds current Waikato DHB Generic Medicine Management and IV certification plus Guardrails competency as well as Neonatal specific competency NCV/NAC (if administering via CVAD).

Guardrails Information

Magnesium is not currently Guardrail profiled on the CC pump for NICU, but will be shortly

Guardrails Drug Name	Magnesium*
Concentration (mmol/mL)	
Minimum	0.01
Maximum	0.08
Dose rate (mmol/kg/hr)	
Default	0.1
Soft minimum	0.09
Soft maximum	0.8
Hard max	1.2

References

- Australasian Consensus Group. Magnesium monograph 2021. <https://www.anmfonline.org/clinical-resources/>
- NZ Formulary for Children (NZFC) v115. Magnesium. https://www.nzfchildren.org.nz/nzf_1417 and https://www.nzfchildren.org.nz/nzfc_70273
- Truven Health Analytics Inc. Pediatrics and Neofax®. 2022. Magnesium sulfate monograph. <http://www.micromedexsolutions.com>.
- Phelps SJ, Hagemann TM, Lee KR, Thompson AJ. The Teddy Bear Book: Pediatric Injectable Drugs. 10th edition. American Society of Health-System Pharmacists; 2013.
- Paediatric Injectable Guidelines. The Royal Children's Hospital Melbourne. <https://pig.rch.org.au>.
- King Edward Memorial Hospital & Perth Children's Hospital Neonatal Medication monograph for Magnesium <https://www.kemh.health.wa.gov.au/~media/HSPs/NMHS/Hospitals/WNHS/Documents/Clinical-guidelines/Neonatal-MPs/Magnesium.pdf?thn=0>
- South Australian Neonatal Medication Guideline Magnesium sulfate
- Notes on Injectable Drugs 2022. New Zealand Hospital Pharmacists Assoc. Inc. <https://www.noids.nz/wp-content/uploads/2020/11/Magnesium-sulfate-heptahydrate-S.pdf>
- The Australian Injectable Drugs Handbook, 8th ed. 2020. Society of Hospital Pharmacists of Australia.
- Ainsworth SB. Neonatal Formulary: Drug Use in Pregnancy and the First Year of Life 8th ed. <https://oxfordmedicine.com/view/10.1093/med/9780198840787.001.0001/med-9780198840787-chapter-25>

Note: Printed copies are only valid on the day of printing – they are not controlled and may not be the current version in use. Please refer to the online version.

Disclaimer: This document has been developed by Waikato District Health Board specifically for its own use. Use of this document and any reliance on the information contained therein by any third party is at their own risk and Waikato District Health Board assumes no responsibility whatsoever.